-
公开(公告)号：US07705117B2
公开(公告)日：2010-04-27
申请号：US11656882
申请日：2007-01-22
Applicant: W. Michael Kavanaugh , Hui Cen , Pauline Lee
Inventor： W. Michael Kavanaugh , Hui Cen , Pauline Lee
CPC classification number: C07K14/4756 , A61K38/00
Abstract: This invention relates to mouse and human EGFH2, and to variants thereof and to polynucleotides encoding EGFH2. This invention also relates to therapeutic agents related to the polynucleotides and proteins.
Abstract translation: 本发明涉及小鼠和人EGFH2及其变体，以及编码EGFH2的多核苷酸。 本发明还涉及与多核苷酸和蛋白质相关的治疗剂。
-
公开(公告)号：US06825333B1
公开(公告)日：2004-11-30
申请号：US09640041
申请日：2000-08-15
Applicant: W. Michael Kavanaugh , Hui Cen , Pauline Lee
Inventor： W. Michael Kavanaugh , Hui Cen , Pauline Lee
IPC: C07H2104
CPC classification number: C07K14/4756 , A61K38/00
Abstract: This invention relates to mouse and human EGFH2, and to variants thereof and to polynucleotides encoding EGFH2. This invention also relates to therapeutic agents related to the polynucleotides and proteins.
Abstract translation: 本发明涉及小鼠和人EGFH2及其变体，以及编码EGFH2的多核苷酸。 本发明还涉及与多核苷酸和蛋白质相关的治疗剂。
-
公开(公告)号：US07276587B2
公开(公告)日：2007-10-02
申请号：US10931285
申请日：2004-08-31
Applicant: W. Michael Kavanaugh , Hui Cen , Pauline Lee
Inventor： W. Michael Kavanaugh , Hui Cen , Pauline Lee
IPC: C07K16/00
CPC classification number: C07K14/4756 , A61K38/00
Abstract: This invention relates to mouse and human EGFH2, and to variants thereof and to polynucleotides encoding EGFH2. This invention also relates to therapeutic agents related to the polynucleotides and proteins.
Abstract translation: 本发明涉及小鼠和人EGFH2及其变体，以及编码EGFH2的多核苷酸。 本发明还涉及与多核苷酸和蛋白质相关的治疗剂。
-
公开(公告)号：US20120165245A1
公开(公告)日：2012-06-28
申请号：US12947939
申请日：2010-11-17
Applicant: Martha J. Whitehouse , W. Michael Kavanaugh
Inventor： Martha J. Whitehouse , W. Michael Kavanaugh
CPC classification number: A61K38/1825 , A61K31/726 , C07K14/50
Abstract: The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
Abstract translation: 本发明提供了包含0.2μg/ kg至36μg/ kg的重组FGF或其血管生成活性片段或突变蛋白的单位剂量。 还提供了包含血管生成有效剂量的FGF或其血管生成活性片段或突变蛋白和药学上可接受的载体的药物组合物。 还提供了治疗人类患者冠状动脉疾病的方法，包括向所述患者的至少一个冠状血管施用安全和血管生成有效剂量的SEQ ID NO：1-3,5,8中任一项的重组FGF -10或12-14，或其血管生成活性片段或突变蛋白。
-
5.发明授权公开(公告)号：US07858584B2
公开(公告)日：2010-12-28
申请号：US12391956
申请日：2009-02-24
Applicant: Martha J. Whitehouse , W. Michael Kavanaugh
Inventor： Martha J. Whitehouse , W. Michael Kavanaugh
CPC classification number: A61K38/1825
Abstract: The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. In another aspect, the present invention is directed to a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Typically, the angiogenically effective dose comprises 0.2 μg/kg to 36 μg/kg of an FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14 or an angiogenically active fragment or mutein thereof. In yet another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF of any one of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
Abstract translation: 本发明具有多个方面。 特别地，一方面，本发明涉及包含0.2μg/ kg至36μg/ kg重组FGF或其血管生成活性片段或突变蛋白的单位剂量。 在另一方面，本发明涉及包含血管生成有效剂量的FGF或其血管生成活性片段或突变蛋白和药学上可接受的载体的药物组合物。 通常，血管生成有效剂量包含0.2μg/ kg至36μg/ kg SEQ ID NO：1-3,5,8-10或12-14中任一项的FGF或其血管生成活性片段或突变蛋白。 另一方面，本发明涉及用于治疗冠状动脉疾病的人类患者的方法，包括对需要治疗冠状动脉疾病的人类患者的至少一个冠状血管施用安全和血管生成有效剂量的 SEQ ID NO：1-3,5,8-10或12-14中任一项的重组FGF或其血管生成活性片段或突变蛋白。
-
Patent Agency Ranking
6.发明授权Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers 失效使用NRG4或其抑制剂治疗结肠癌和胰腺癌公开(公告)号：US07476506B2
公开(公告)日：2009-01-13
申请号：US11704622
申请日：2007-02-09
Applicant: Siew C. Schleyer , Anne B. Jefferson , Judith A. Abraham , W. Michael Kavanaugh
Inventor： Siew C. Schleyer , Anne B. Jefferson , Judith A. Abraham , W. Michael Kavanaugh
IPC: C12Q1/68
CPC classification number: C07K14/4756 , A61K2039/505 , C07K16/22 , C12Q1/6886 , C12Q2600/16 , G01N33/57419 , G01N2333/485
Abstract: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.
Abstract translation: 本发明涉及治疗和诊断目的，特别是与结肠癌和胰腺癌相关的NRG4及其变体和编码NRG4的多核苷酸的组合物和用途。 本发明还涉及基于或衍生自多核苷酸和蛋白质的NRG4抑制剂，特别是能够特异性结合NRG4的抗体。
-
7.发明授权Use of FGFR1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in FGFR2 有权使用FGFR1细胞外结构域蛋白来治疗FGFR2中配体依赖性激活突变特征的癌症公开(公告)号：US08614183B2
公开(公告)日：2013-12-24
申请号：US13509068
申请日：2010-11-12
Applicant: Thomas Harding , W. Michael Kavanaugh
Inventor： Thomas Harding , W. Michael Kavanaugh
IPC: A61K39/00 , A61K38/18 , C07K14/475 , C07K14/50
CPC classification number: C07K14/71 , A61K38/179 , A61K38/1825
Abstract: The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253.
Abstract translation: 本发明涉及成纤维细胞生长因子受体I（FGFR1）细胞外结构域（EGFR）多肽用于治疗以成纤维细胞生长因子受体2（FGFR2）中配体依赖性激活突变为特征的癌症的用途。 例如，本发明涉及治疗子宫内膜癌和其它癌症，其中肿瘤细胞在蛋白质的IgII-IgIII铰链区或IgIII结构域中表达FGFR2突变体，例如在氨基酸位置252和/或253。
-
公开(公告)号：US08445445B2
公开(公告)日：2013-05-21
申请号：US13496182
申请日：2010-09-15
Applicant: Thomas Brennan , Robert Dean , W. Michael Kavanaugh , Janine Powers
Inventor： Thomas Brennan , Robert Dean , W. Michael Kavanaugh , Janine Powers
IPC: A61K38/00 , A61K38/18 , A61K38/16 , C07K14/475 , C07K14/50
CPC classification number: A61Q7/00 , A61K8/64 , A61K2800/86
Abstract: The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 4 (FGFR4) extracellular domain (ECD), including native FGFR4 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth.
Abstract translation: 促进毛发生长的方法本发明涉及一种促进毛发生长的方法，其包括以足以促进毛发生长的量给予受试者的成纤维细胞生长因子受体4（FGFR4）细胞外结构域（ECD），包括天然FGFR4 ECD，变体，片段和融合分子 头发生长。
-
公开(公告)号：US20080200378A1
公开(公告)日：2008-08-21
申请号：US11787428
申请日：2007-04-16
Applicant: Denis J. Gospodarowicz , W. Michael Kavanaugh , Kenneth Crawford
Inventor： Denis J. Gospodarowicz , W. Michael Kavanaugh , Kenneth Crawford
CPC classification number: C07K14/50 , A61K38/1825
Abstract: Compositions comprising keratinocyte growth factor (KGF) polypeptides and methods of using the same are described. The KGF polypeptides of the present invention display enhanced bioactivity relative to full-length KGF163. Accordingly, the KGF polypeptides of the present invention may be used in compositions in lesser amounts than would be necessary using KGF163.
Abstract translation: 描述了包含角质形成细胞生长因子（KGF）多肽的组合物及其使用方法。 本发明的KGF多肽相对于全长KGF 163显示增强的生物活性。 因此，本发明的KGF多肽可以以比使用KGF 163的必需量少的组合物使用。
-
10.发明授权Method for inducing angiogenesis or vascular perfusion in the myocardium comprising administering FGF-2 有权用于诱导心肌中血管生成或血管灌注的方法，包括给予FGF-2公开(公告)号：US07531511B2
公开(公告)日：2009-05-12
申请号：US11220027
申请日：2005-09-06
Applicant: David T. Hung , Brian H. Annex , Kevin P. Landolfo , W. Michael Kavanaugh
Inventor： David T. Hung , Brian H. Annex , Kevin P. Landolfo , W. Michael Kavanaugh
CPC classification number: A61K38/1858 , A61K38/1825 , A61K38/1866
Abstract: The present invention has multiple aspects. In one aspect, the present invention is directed to a unit dose pharmaceutical composition comprising from about 5 ng/dose to less than 135,000 ng of an angiogenic agent, typically from 5 ng to 67,500 ng. Preferably, the angiogenic agent is FGF, more preferably it is basic FGF (FGF-2). In its second aspect, the present invention is directed to a method for inducing angiogenesis, or increasing myocardial perfusion or vascular density in a patient's heart, comprising administering directly into the myocardium in an area in need, as a single injection or a series of injections, a unit dose of an angiogenic agent. It is also within the scope of the present invention that a plurality of unit dose compositions be administered directly into the myocardium at a plurality of sites in need of angiogenesis. In another aspect, the present invention is directed to a method for treating a patient for coronary artery disease, comprising administering directly into the myocardium in an area of need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent. In yet another aspect, the present invention is directed to a method for treating a patient for a myocardial infarction, comprising administering directly into the myocardium in an area in need of angiogenesis in said patient, a unit dose (i.e., from about 5 ng to less than 135,000 ng) of an angiogenic agent.
Abstract translation: 本发明具有多个方面。 一方面，本发明涉及包含约5ng /剂量至小于135,000ng血管生成剂（通常为5ng至67,500ng）的单位剂量药物组合物。 优选地，血管生成剂是FGF，更优选是碱性FGF（FGF-2）。 在其第二方面，本发明涉及用于诱导血管发生或增加患者心脏中的心肌灌注或血管密度的方法，包括在需要的区域中直接施用于心肌，作为单次注射或一系列注射 ，血管生成剂的单位剂量。 在本发明的范围内，多个单位剂量组合物可以在需要血管生成的多个部位直接施用于心肌。 另一方面，本发明涉及一种治疗患者冠状动脉疾病的方法，其包括在所述患者中需要血管生成的区域中直接对心肌施用单位剂量（即约5ng至少约5ng至 超过135,000ng）血管生成剂。 另一方面，本发明涉及用于治疗患者心肌梗塞的方法，包括在所述患者中需要血管生成的区域中直接施用心肌，单位剂量（即约5ng至 小于135,000ng）血管生成剂。
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.04 seconds)
